Sarcopenia, or the decline of skeletal muscle tissue with age, is one of the most important causes of functional decline and loss of independence in older adults. The purpose of this article is to review the current definitions of sarcopenia, its potential causes and clinical consequences, and the potential for intervention.
INTRODUCTION
Sarcopenia has been defined as an age related, involuntary loss of skeletal muscle mass and strength. Beginning as early as the 4th decade of life, evidence suggests that skeletal muscle mass and skeletal muscle strength decline in a linear fashion, with up to 50% of mass being lost by the 8th decade of life [1] . Given that muscle mass accounts for up to 60% of body mass, pathological changes to this important metabolically active tissue can have profound consequences on the older adult. The consequences of sarcopenia are often severe in older adults, as the strength and functional declines associated with sarcopenia can in turn contribute to a number of adverse health outcomes, including loss of function, disability, and frailty [2,3,4 & ]. Sarcopenia is also associated with acute and chronic disease states, increased insulin resistance, fatigue, falls, and mortality [5] [6] [7] . Of the chronic disease states, sarcopenia has been especially associated with rheumatologic conditions, especially rheumatoid arthritis (RA) in women [8] .
The physiological and morphological changes in skeletal muscle with advancing age are characterized by overall declines in size and number of skeletal muscle fibers, mainly the type 2 or fast-twitch muscle fibers, and a marked infiltration of fibrous and adipose tissue into the skeletal muscle [9] . In addition, satellite cells, the skeletal muscle precursor cells that reside in a quiescent state in association with myofibrils, likely also undergo important aging-related changes. These satellite cells are activated and begin the process of skeletal muscle repair and regeneration in response to the stress of heavy muscle use such as with weight-bearing activities or through traumatic events such as injury [10] . In the skeletal muscle of older adults, the satellite cell content is reduced and most specifically in the type-2 skeletal muscle fibers [11] .
Although aging-related biological changes clearly drive sarcopenia, it is increasingly clear that obesity and fat infiltration into skeletal muscle play an important role in sarcopenia [12, 13] . This phenomenon, termed sarcopenic obesity, is often grouped together with sarcopenia and likely plays an important role in a subset of those older adults thought to have sarcopenia. An analysis in the Framingham Study recently highlighted the functional and mobility limitations in sarcopenic obesity [2] . Investigators with the Health, Aging and Body Composition Study [14 & ], a longitudinal study of age-related changes in skeletal muscle and body composition in older adults, recently identified that increased fat mass was associated with lower muscle quality and an accelerated loss of lean body mass over 8 years.
The following review article briefly summarizes the ongoing debate over a clinical definition of sarcopenia, the multifactorial cause of sarcopenia, and the potential for intervention.
CLINICAL DEFINITION OF SARCOPENIA
A consensus clinical definition of sarcopenia or sarcopenic obesity does not presently exist. This is in part because of the lack of standardized measurements that capture functional skeletal muscle mass, because skeletal muscle mass measurements do not capture functionality, and because there has been no consensus in the research or clinical communities regarding its definition [15] . Many prior studies have used either muscle mass, muscle strength, or physical function measurements alone or in combination as markers for sarcopenia [16 & ]. In the past few years, investigators and clinicians have advocated for the inclusion of muscle strength or functional measurements related to strength such as grip strength and/or walking speed along with a muscle mass measurement in order to improve the diagnostic accuracy of sarcopenia [17] . Recent consensus conferences have been organized in order to move toward an acceptable clinical definition that can be utilized for both diagnosis and clinical research purposes. For example, the Society of Sarcopenia, Cachexia, and Wasting Disorders recently published a definition of sarcopenia with limited mobility that used a measure of walking speed and muscle mass [18] . The European Working Group on Sarcopenia in Older People (EWGSOP) recently recommended that measures of low muscle mass and low muscle strength or performance be utilized in any clinical definition [19] . This working group also has helped to provide important updates on currently available cut points for specific musclerelated measurements, and highlights the need for additional empirical data to be collected to facilitate the operationalization and validation of a sarcopenia diagnostic screening methodology that can be reproduced across many populations and integrated in Geriatrics practice.
CAUSES OF SARCOPENIA
The cause of sarcopenia is generally thought to be multifactorial, with environmental causes, disease triggers, inflammatory pathway activation, mitochondrial abnormalities, loss of neuromuscular junctions, reduced satellite cell numbers, and hormonal changes all thought to contribute ( Fig. 1 ). In addition to these causes, recent progress in the understanding of molecular pathways that contribute to skeletal muscle maintenance has helped to further highlight Tissue growth factor (TGF)-b signaling, apoptosis activation, and declines in mitochondrial function as potentially important in triggering sarcopenia as described in more detail below.
Environmental causes are usually divided between declines in activity and declines in nutritional intake. Older adults are less active, in part because of the increased chronic disease burden that leads to pain and fatigue [20] . In addition, declines in adequate protein and calorie intake, as well as overnutrition that results in sarcopenic obesity and accelerated loss of muscle mass and function, are important contributors to sarcopenia in older adults [14 & ,21] . Taken together, these environmental influences are superimposed on
KEY POINTS
Sarcopenia is a common condition in older adults that contributes to functional decline, disability, frailty, and falls.
There is as of yet no consensus definition for sarcopenia, although recommendations for the development of a definition based on both muscle mass measurement and physical function have been proposed.
Sarcopenia has a multifactorial cause, with declines in activity and nutrition, disease states, inflammation, declines in neuromuscular junctions, and aging related changes in mitochondria, apoptosis, and the angiotensin system recently found to be contributory.
Rheumatological conditions are highly associated with sarcopenia/skeletal muscle mass decline, likely due to the high levels of inflammatory cytokines.
Clinical interventions have focused on exercise and nutrition, with pharmaceutical testing lagging in part because of the lack of a consensus definition. a multifactorial, age-related change in biology that pushes toward declines in skeletal muscle mass and strength as described below.
First, declines in the number of neuromuscular junctions, with resulting drop out of fast-twitch or type-II muscle fibers is thought to be play an important role in age-related muscle decline [22] . Recent studies in older female mice have demonstrated striking increases in the percentage of fully denervated neuromuscle junctions, especially in the fast-twitch muscle fibers such as in the extensor digitorum longus [23 & ]. Interestingly, the number of motor neurons in the spinal cord that innervate this area is not decreased, suggesting that this may be an axonal decline rather than a nerve body change per se. Because of the potential importance of this loss to the development of sarcopenia in humans, a potentially important new diagnostic screening measurement, the C-terminal agrin fragment, has been identified as a marker of neuromuscular junction decline in older men [24] . Second, declines in hormones that are important in muscle mass maintenance, including insulin-like growth factor-1, Dehydroepiandrosterone sulfate, testosterone, and estrogen, all likely contribute to sarcopenia [25, 26] . These pathways also offer important potential opportunities for interventions [27] . Third, inflammatory pathway activation, likely due to a variety of disease and aging causes, is known to be an important contributor to sarcopenia [28] . A study [29] of serum levels of the inflammatory cytokine interleukin-6 and its relationship to muscle strength in older women demonstrated a steeper decline in walking ability, a higher risk of developing physical disability, explained in part by a parallel decline in skeletal muscle strength. This may be in part due to the important influence of chronic inflammatory cytokine exposure on satellite cells in muscle fibers. The contribution of inflammation in older adults can come from multiple sources. Certainly, chronic disease states are among the most common triggers of inflammatory pathway activation. Many inflammatory rheumatological conditions such as systemic lupus erythematosus and RA are associated with muscle loss that is thought to be related to the chronic activation of inflammatory pathways that in turn negatively influence muscle regeneration [30 & ]. Many other chronic conditions, including renal failure and congestive heart failure, likely accelerate the development of sarcopenia via the increase of inflammatory mediators [31] .
Finally, the aging-related loss of ability to replenish and replace skeletal muscle is increasingly evident. Skeletal muscle stem cells, crucial to the regeneration of skeletal muscle in older and younger adults, appear to be compromised in older adults in that they migrate at much slower speeds than younger cells, and their motility is hampered perhaps in part because of low levels of integrin expression [32 && ].
Newer molecular findings related to sarcopenia
Underlying the more physiological causes outlined above are a host of age-related and disease-related biological changes that increase the vulnerability of older adults to the development of sarcopenia [16 & ]. Some important new studies have helped to shed light on aging-related molecular triggers for sarcopenia. Mitochondrial function and mitochondrial biogenesis appear to be altered in skeletal muscles of older adults, which in turn may contribute to altered skeletal muscle mass and function [33 && ]. Aging-related changes in the angiotensin system were recently identified to play a crucial role in skeletal muscle healing and in disuse atrophy of skeletal muscle [34 && ]. Importantly, in this same study, the angiotensin type-1 receptor blocking agent losartan was found to help accelerate skeletal muscle healing and prevent disuse atrophy in treated older mice, likely in response to downregulation of the TGF-b pathways. Losartan was also demonstrated to increase the number of angiotensin type-2 receptors in the mitochondria of older mice, which in turn explains some of the improved skeletal muscle healing that was observed in older mice treated with losartan [35 & ]. Apoptosis, or programmed cell death may also play an important role in sarcopenia development. Preliminary studies of proteins associated with apoptosis showed an upregulation in those older adults with lower thigh muscle volume and slower gait speed, suggesting that apoptosis may contribute to this muscle decline. The apoptosisinducing factor, usually located in the intermitochondrial membrane space, was recently found to protect skeletal muscle precursors, or satellite cells, from apoptosis so long as it was not released into the cytoplasm of cells [36] . Finally, newer evidence suggests that altered transcriptional regulation of mRNA and translation of proteins negatively impact proteins important in myogenesis, including Pax 7, myogenin, and MyoD [37] .
Interventions for sarcopenia
Although substantial progress has been made in the understanding of the multifactorial causes of sarcopenia, most interventions have focused on improving the environmental causes of sarcopenia, namely through increasing activity and providing adequate nutrition. Given the high prevalence of sarcopenia, and close relationship to fatigue, functional decline, and chronic illness, the development of interventions has been touted by drug companies and investigators as a crucially important target for intervention in older adults [38] . Although a largescale clinical trial that targets the prevention or treatment of sarcopenia per se has not been attempted, many studies have indirectly targeted sarcopenia by using age-related declines in physical function as an outcome. Results of clinical intervention studies in even the oldest and frailest nursing home residents have demonstrated significant functional improvement through a combination of nutrition and resistance exercise [39] . Recent clinical studies continue to show this with significant increases in muscle protein synthesis in older adults who receive physical activity and nutrition [40 ,41] . These interventions appear to positively impact satellite cell dysfunction, neuromuscular junction decline, and mitochondrial biogenesis. Although endocrine interventions targeting muscle function and strength have been developed previously, few, if any, have shown efficacy [26] . Future pharmaceutical interventions for sarcopenia will also likely target very specific molecular pathways such as the angiotensin system, apoptosis, and mitochondrial function.
In order to develop the next generation of studies targeting sarcopenia per se, it will be important to develop a consensus definition that can be utilized across a number of studies and populations in order to determine safety and efficacy for sarcopenia. The International Working Group on Sarcopenia has developed recommendations on the design of phase IIB clinical trials and cautions that appropriate muscle mass measurements and physical function measurements, along with sufficient periods of time, are necessary to adequately test any proposed pharmaceutical intervention [42] . EWGSOP also strongly recommends that measures of muscle mass, muscle strength, and/or functional performance be utilized in any clinical definition [19] , which will help to facilitate the operationalization and validation of a sarcopenia diagnostic screening methodology that can be reproduced across many populations, used in clinical trials, and integrated into the practice of geriatric medicine.
CONCLUSION
Sarcopenia remains an important clinical problem that impacts millions of older adults. Despite its high prevalence, no clear consensus definition has been developed. Causes include declines in hormones and numbers of neuromuscular junctions, increased inflammation, declines in activity, and inadequate nutrition. Newer molecular discoveries that may impact sarcopenia include alterations in mitochondrial biology, the angiotensin system, and apoptosis. Interventions for sarcopenia continue to be developed with most emphasis on exercise and nutritional interventions. Pharmaceutical development has in part been slowed by the lack of a consensus definition for sarcopenia.
